ascopubs.org

A phase I study of EMD 525797, a novel humanized monoclonal antibody to human integrin alpha v, in Japanese patients with solid tumor.

A model-based approach to optimize detection of treatment effects in early oncology trials. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3 ...

Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM) ...